According to the Market Statsville Group (MSG), the Global RNA Analysis Market size is expected to grow from USD 9,988.1 million in 2021 to USD 31,220.6 million by 2030 at a CAGR of 13.5% from 2022 to 2030. RNA analysis is a high-throughput sequencing technique used to determine the transcriptome of a cell. RNA-sequencing is a technique that employs next-generation sequencing (NGS) to determine the amount and sequences of RNA in a sample. It examines the transcriptome to find out which genes are encoded in DNA. RNA analysis can diagnose the diseases and systems that cause death, making it an important analytical tool in forensic pathology for identifying the cause of death. RNA species aid the translation of genetic information from DNA to proteins (messenger RNA, transfer RNA, and ribosomal RNA).

The increasing demand for personalized medicine, increasing pharmaceutical and biotechnology R&D expenditure, government funding for omics, and the increasing uses of RNA sequencing in the transcriptomics industry are all driving this market's growth. The growing focus on biomarker discovery and toxicogenomics, as well as the growing interest in outsourcing services, is likely to provide considerable prospects for the global RNA analysis/transcriptomics market. On the other hand, the high capital investment requirements and data management concerns are projected to limit the market's growth to some extent.

COVID-19 Impact on the RNA analysis market

Due to Next-Generation Sequencing-NGS and Polymerase Chain Reaction-PCR, which are expected to drive market growth during the COVID 19 pandemic, there is an increased necessity for testing and diagnosis. COVID-19 is an infectious disease, and its global prevalence is expected to increase throughout the forecast period. For the investigation and inspection of the infection, RNAs are isolated from the BAL- Bronchoalveolar lavage fluid of the COVID patient and sequenced. This is being utilized to give clinical advice on anti-inflammatory drugs and better understand the host's molecular structure and reaction to design effective remedies.

As a result, the increasing number of COVID-19 cases is driving up demand for testing and research, further boosting the market’s growth. The World Health Organization (WHO) announced in March 2020 that new tests and testing kits would be produced to meet the global requirement for pandemic diagnosis. According to the World Health Organization (WHO), around 1.5 million tests have been distributed to 120 countries, encouraging key players and manufacturers to increase test availability for people most in need during the pandemic.

Scope of the RNA analysis market

The study categorizes the RNA analysis market based on product, technology, application, and end-user at regional and global levels.

By Product Outlook (Sales, USD Million, 2017-2030)

• Reagents/Consumables
• Instruments
• Software
• Services

By Technology Outlook (Sales, USD Million, 2017-2030)

• Microarrays
• Sequencing
• Polymerase Chain reaction (PCR)
• RNA Interference

By Application Outlook (Sales, USD Million, 2017-2030)

• Clinical Diagnostics
• Drug Discovery
• Toxicogenomics
• Comparative Transcriptomics

By End User Outlook (Sales, USD Million, 2017-2030)

• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Hospitals
• Contract Research Organizations

By Region Outlook (Sales, USD Million, 2017-2030)

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Italy
  • France
  • UK
  • Spain
  • Poland
  • Russia
  • Slovenia
  • Slovakia
  • the Netherlands
  • Belgium
  • Norway
  • Denmark
  • Czech Republic
  • Sweden
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Malaysia
  • Thailand
  • Vietnam
  • the Philippines
  • Singapore
  • Australia & New Zealand
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Rest of South America
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Northern Africa
  • Rest of MEA

Reagents/Consumables segment is projected to account for the largest market share, by product

Based on product, the RNA analysis market is divided into reagents/consumables, instruments, software, and services. During the COVID pandemic, demand for detection and diagnosis is expected to rise, boosting the segment's growth. Increased infectious diseases and oncological occurrences are expected to increase segmental growth throughout the forecast period. The use of medium and reagents in transcriptome studies is increasing, as is the demand for high-quality reagents. The pharmaceutical industry's increased R&D efforts, government spending on life science research, and the growing research done with integrated omics studies are all helping to drive the consumables market. The rising incidence of chronic diseases, the rising number of hospital admissions due to infectious diseases, and rising healthcare expenditures are all factors that are expected to boost demand for regents/consumables and push the market ahead. COVID -19 has enhanced regent/consumable consumption in various end users, including hospitals and diagnostic centers. Consumables' increasing penetration propels the segment's growth in the market.

North America is expected to hold the largest share in the market and is expected to do continue in the forecast period

Based on the regions, the RNA analysis market has been analyzed across five major regions: North America, Asia Pacific, the Middle East & Africa, Europe, and Latin or South America. North America is expected to hold the largest market share in the global RNA analysis market due to the increasing prevalence and incidence of cancer and infectious diseases in this region.  North America had a large market share for RNA analysis in 2021, and this trend is expected to continue in the forecast period. According to the American Cancer Society, around 1.9 million instances of cancer were discovered in the United States in 2021, with 608,570 deaths reported. As per the American Cancer Society, a special section was held in 2021 to focus on the people affected by COVID-19 and cancer, as well as the overall American healthcare system. Furthermore, the rise of such activities and the presence of favourable healthcare infrastructure are driving the overall regional market growth to a great extent.

Rising demand for various assay technologies, quantification of multiplexed RNA, growing need for genetic testing and personalized treatment, and an increase in genetic variety and mutation occurrences are all driving the market in the area. North America is the most prominent area due to a large number of biotech companies with well-established infrastructure and cutting-edge technology platforms. Expanding prospects, increased healthcare expenditures, and implementing government programmes are among the other factors driving market expansion.

Key Market Players in RNA analysis market

The RNA analysis market  is mildly concentrated in nature, with few numbers of global players operating in the market, such as:

• Thermo Fisher Scientific, Inc.
• Bio-Rad Laboratories, Inc.
• Merck KGaA
• Agilent Technologies, Inc.
• Illumina, Inc.
• QIAGEN N.V.
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Fluidigm Corporation
• Eurofins Scientific
• Sequentia Biotech SL
• Acobiom
• GenXPro GmbH
• CD Genomics
• Promega Corporation
• Lexogen GmbH
• Cenix BioScience GmbH
• Cenix BioScience GmbH

Recent Developments

•   In February 2022, eTheRNA announced a research agreement with Merck KGaA to develop mRNA design expertise and LNP-delivery technologies.
•  In April 2021, Oxford Brookes University acknowledged the breakthrough of new single-cell transcriptomic technologies. These technologies evaluate several individual cells from living organisms and sequence each cell's genetic material.
•  In January 2021, Merck announced the acquisition of AmpTec  to expand its product portfolio for mRNA for Vaccines, Treatments, and Diagnostics.
•  In September 2020, Agilent Technologies introduced the SureSelect XT HS2 RNA Reagent Kit
• In April 2019, Agilent and SomaLogic signed an agreement under which Agilent will provide the customized high-fidelity oligo microarrays for use in SomaLogic's innovative SOMAscan assay's nucleic acid detection steps.

Key Issues Addressed

• What is the market size by various segmentation of the RNA analysis by region and its respective countries?
• What is the customer buying behavior, key takeaways, and Porter's five forces of the RNA analysis Market?
• What are the key opportunities and trends for manufacturers involved in the RNA analysis supply chain?
• What are the market's fundamental dynamics (drivers, restraints, opportunities, and challenges)?
• What and how are regulations, schemes, patents, and policies impacting the market's growth?
• What are the upcoming technological solutions influencing market trends? How will existing companies adapt to the new change in technology?
• The market player positioning, top winning strategies by years, company product developments, and launches will be?
• How has COVID-19 impacted the demand and sales of RNA analysis in the global market? Also, the expected BPS drop or rise count of the market and market predicted recovery period.
• Detailed analysis of the competitors and their latest launch, and what are the prominent startups introduced in the target market? Also, detailed company profiling of 25+ leading and prominent companies in the market.